A biothreat agent is defined as a biological weapon employed to deliberately cause disease, but how real are such threats, and what should our approach be towards them?
Microbial domain biological resource centers that provide researchers with access to living cultures of microorganisms have adopted a code of conduct and best practice to prevent the misappropriation and misuse of microorganisms.
A new analysis has suggested that the notion of ‘completing the course’ when taking antibiotics is not evidence-based and should be dropped as it may actually increase the risk of antibiotic resistance.
In this interview, Roy Anderson, Director for the London Centre for Neglected Tropical Disease Research speaks about the work undertaken by the Centre and gives his thoughts on the wider NTD field.
Despite an urgent need for a universal flu vaccine there is no such vaccine in the market and no regulatory guideline for its approval. This special report from Future Virology proposes a stepwise process for regulatory and marketing approval for such a vaccine and discusses the epitope-based vaccine candidate Multimeric-001 (M-001).
In this editorial the author examines the initiatives taken by Drugs for Neglected Diseases (DNDi) and Medicines Patent Pool (MPP) organizations to improve access to pan-genotypic hepatitis C treatment.
The WHO has published a report this week listing 12 families of antibiotic-resistant bacteria that are thought to pose the greatest public health risk and should be the focus for new treatments.
Influenza, immunopathogenesis, and the interface of research and policy – an interview with Peter Openshaw
We at Infectious Diseases Hub recently spoke to Peter Openshaw, Professor of Experimental Medicine at Imperial College London (UK), about his research into respiratory viruses and the challenges currently facing science policy and funding.